ASH 2013: Rocky day for Infinity on IPI-145 data
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals found itself in a tough spot on 9 December after the Cambridge, Massachusetts-based company reported positive data from an ongoing Phase I clinical trial for its PI3K-delta and PI3K-gamma inhibitor IPI-145.